依托泊甙联合顺铂治疗食管小细胞癌的疗效  

VP-16/DDP Combination as A First-line Regimen for Esophageal Small Cell Carcinoma

作　　者：刘莺[1] 曹婧[2] 张艳玲[1] 刘文静[1] 李克[1] 王居峰[1] 

机构地区：[1]河南省肿瘤医院内科,郑州450003 [2]郑州铁路职业技术学院

出　　处：《肿瘤防治研究》2011年第12期1423-1425,共3页Cancer Research on Prevention and Treatment

摘　　要：目的观察依托泊甙(VP-16)联合顺铂(DDP)治疗食管小细胞癌的疗效及不良反应。方法局限期(LD)患者7例,广泛期(ED)患者9例,所有患者均接受VP-16/DDP方案联合化疗。结果 LD组CR1例(14%),PR4例(57%),PD1例(14%),总有效率71%(CR+PR);ED组:CR0例,PR5例(56%),总有效率56%(CR+PR)。LD组:中位至疾病进展时间(TTP)19月(95%CI:6.1～25.1月),中位生存时间(OS)24.7月(95%CI:10.5～36.7月)。ED组:中位至疾病进展时间(TTP)8.2月(95%CI:5.7～16.9月),中位生存时间(OS)12.5月(95%CI:9.5～25.1月)。LD组和ED组中非血液学毒性发生率最高的是消化道反应,Ⅰ～Ⅱ级恶心呕吐发生率分别为:72%和44%;Ⅲ～Ⅳ级白细胞减少的发生率分别为43%和33%;本研究中无治疗相关性死亡。结论依托泊甙联合顺铂治疗食管小细胞癌疗效显著,耐受性好。Objective To evaluate the efficiency and safety of combination therapy with VP-16 and Cisplatin in esophageal small cell carcinoma.Methods Seven of the sixteen patients were staged limited（LD） disease,the other nine patients were staged extend disease（ED）.All the patients received etoposide 100 mg/m2 2 h infusion from d1 to d3 combined with Cisplatin 80 mg/m2 2 h infusion on d1,and the regimen was repeated every three weeks.Concurrently,the patients with limited disease received radiation therapy： 50 Gy,in daily doses of 2 Gy,5 d/w.Results In LD group,there was 1 patient experienced CR,4 patients PR（57.1%）,and the ORR was 71%（CR＋PR）.The TTP was 19 months,and OS was 24.7 months.While in ED group,no patient was CR,5 patients PR（56%）,and the ORR was 56%.The TTP was 8.2 months,and OS was 12.5 months.Both in LD group and ED group there were grade 3~4 hematological toxicity： loucopenia（43% vs.33%）.No hematological toxicity consisted mainly of grade 1~2 nausea/vomiting（72% vs.44%）.Furthermore,no treatment-related deaths were observed.Conclusion The combination of VP-16 and DDP appears to be effective therapy for esophageal small cell carcinoma with acceptable toxicity.

关 键 词：依托泊甙 顺铂 食管小细胞癌 联合化疗 

分 类 号：R730.53[医药卫生—肿瘤] R735.1[医药卫生—临床医学]